POLITZ, Circuit Judge:
Automated Medical Laboratories, Inc. (Auto) operated several plasmapheresis centers and sold the plasma collected to Armour Pharmaceutical Company (Armour), a Phoenix-based business engaged in the purchase and processing of raw plasma for human medical needs. A dispute has arisen between the parties as to the validity, reach and breach of their agreement, as well as to damages sustained by each party and the peripheral issue of pre-judgment interest. After a bench trial, the district court (1) awarded Auto damages for breach of contract in the amount of $678,027.96, (2) awarded Armour damages on its cross-complaint for breach of contract in the amount of $109,644.51, and (3) awarded Auto prejudgment interest and costs. We affirm in part, reverse in part, and remand.
We find little meaningful dispute in the material facts, although there is substantial dispute about their meaning and about the application of the controlling rules of law. Lloyd Rothenberg, President of Auto, and Ralph Eacret, the officer in charge of plasma purchases for Armour, had for several years entered into annual oral contracts by which Armour purchased essentially all of Auto’s product. The oral agreements were followed by purchase orders which Armour sent Auto at the beginning of each year. Each month Auto shipped Armour the production from its collection centers.
Based on the relationship which existed between the parties, and assurances by Armour of its interest in purchasing all plasma produced, Auto undertook an expansion program which included the opening of five new centers.
By late 1974, Armour
was purchasing a minimum of 6,000 liters of plasma per month, the entire output of Auto’s six plasmapheresis centers. By January 1975, Auto’s monthly production capacity had reached 15,000 liters, a capability of which Armour was aware. On January 7,1975, Armour issued a purchase order for calendar year 1975, calling for 3,000 liters per month of “Flash Frozen Plasma” at a price of $42.50 per liter. Because of the dramatic reduction in volume Rothenberg promptly called Eacret and they agreed to meet in Phoenix to resolve their differences. In late January 1975, Rothenberg, Eacret, and another representative of Armour, all met in Phoenix. Eacret succinctly detailed the results of that meeting, testifying:
Well, as I recall, an agreement was reached where Automated Medical Labs would supply additional quantities of plasma on the purchase order [for the January to December 1975 period].
[A]t the meeting, Mr. Rothenberg did mention a quantity of 8000 liters per month [and]
we agreed, verbally to purchase that quantity.
(Emphasis added.)
Between January 7, 1975 and mid-April 1975, Armour accepted delivery of and paid the agreed price for 26,884 liters. Also during this period, Armour informed Auto that it could' no longer use “Flash Frozen Plasma,” but would accept “Normal Fresh Frozen Plasma” at a price of $40.50 per liter. Auto’s agreement to this modification was confirmed in writing.
In late March or early April 1975, Roger Bauer, Eacret’s assistant, called Rothenberg to advise that Armour would no longer accept any shipments, citing an excessive inventory and no market. On April 25, 1975, Armour sent Auto the following telegram:
AS DISCUSSED YOUR LAST PLASMA SHIPMENT TO ARMOUR UNTIL FURTHER NOTICE WILL BE DURING THE WEEK OF 4/21/75.
Armour never resumed purchases from Auto, who remained ready and able to supply 8,000 liters per month. In an effort to mitigate its dilemma, Auto secured a German customer who purchased 2,000 liters per month, commencing June 28, 1975. Auto ceased collecting plasma at three of its centers.
In June 1975, Armour was informed by the Bureau of Biologies, Food and Drug Administration (the Bureau) that five units (approximately 3 liters) of plasma shipped from Auto’s Orlando center in 1974 were possibly contaminated with hepatitis. Armour was also informed that plasma from both the Clearwater and Orlando facilities was under quarantine. Armour promptly notified Auto of this information and asserted' that the questioned plasma did not conform to the warranty specifications of their purchase agreement.
After completing its investigation, the Bureau informed Armour that all plasma from Auto’s Clearwater and Orlando centers which Armour had in process of manufacture as of June 6, 1975 was safe and could be sold. All such plasma “in process” had been shipped prior to January 1, 1975. Any resulting warranty breach, therefore, necessarily arose pursuant" to the terms of the parties’ 1974 contract and not the January 1975 Phoenix agreement.
Upon receiving approval from the Bureau on August 27, 1975, Armour tested over 28,000 units of the suspect plasma. Ninety-nine units of plasma tested “hepatitis positive.” Armour incurred expenses totaling $109,644.51 in its program to sample, test, store, and care for the quarantined plasma.
After weighing the evidence adduced at trial, the district court held: (1) that the January 1975 “Phoenix agreement,” requiring Armour to purchase 8,000 liters of plasma per month at $42.50 per liter, was a binding oral contract for the calendar year 1975; (2) that the contract price was mutually modified in March 1975 to $40.50 per liter; (3) that Armour breached and completely repudiated the contract in April 1975; (4) that Auto was entitled to recover
net damages amounting to $678,027.96, as well as pre-judgment interest on this award; and (5) that due to Auto’s breach of warranty resulting from the hepatitis-contaminated blood, Armour sustained $109,-644.51 in damages, which amount was to be offset against Auto’s damage recovery, resulting in a net award to Auto of $568,-383.45.
On appeal, Armour contends that the Phoenix agreement is not a binding contract because it violates the statute of frauds and that Auto is not entitled to pre-judgment interest because its damages are unliquidated. Auto insists that the contract is binding, that it is entitled to gross damages, rather than net damages, and it challenges the breach of warranty recovery awarded Armour.
The Phoenix Agreement: Bad Contract as Well as Bad Blood?
U.C.C. § 2-201
provides that contracts for the sale of goods valued in excess of $500 are unenforceable unless in writing and signed by or for the respondent party.
Armour claims that the Phoenix agreement, providing for the- purchase/sale of 8,000 liters per month throughout 1975, is unenforceable under § 2-201 because it is not in writing.
Invoking the statute of frauds is an affirmative defense which must be specially pled. Fed.R.Civ.P. 8(c). Although absolute specificity in pleading is not required, fair notice of the affirmative defense is. Fed.R. Civ.P. 8(f).
Free access — add to your briefcase to read the full text and ask questions with AI
POLITZ, Circuit Judge:
Automated Medical Laboratories, Inc. (Auto) operated several plasmapheresis centers and sold the plasma collected to Armour Pharmaceutical Company (Armour), a Phoenix-based business engaged in the purchase and processing of raw plasma for human medical needs. A dispute has arisen between the parties as to the validity, reach and breach of their agreement, as well as to damages sustained by each party and the peripheral issue of pre-judgment interest. After a bench trial, the district court (1) awarded Auto damages for breach of contract in the amount of $678,027.96, (2) awarded Armour damages on its cross-complaint for breach of contract in the amount of $109,644.51, and (3) awarded Auto prejudgment interest and costs. We affirm in part, reverse in part, and remand.
We find little meaningful dispute in the material facts, although there is substantial dispute about their meaning and about the application of the controlling rules of law. Lloyd Rothenberg, President of Auto, and Ralph Eacret, the officer in charge of plasma purchases for Armour, had for several years entered into annual oral contracts by which Armour purchased essentially all of Auto’s product. The oral agreements were followed by purchase orders which Armour sent Auto at the beginning of each year. Each month Auto shipped Armour the production from its collection centers.
Based on the relationship which existed between the parties, and assurances by Armour of its interest in purchasing all plasma produced, Auto undertook an expansion program which included the opening of five new centers.
By late 1974, Armour
was purchasing a minimum of 6,000 liters of plasma per month, the entire output of Auto’s six plasmapheresis centers. By January 1975, Auto’s monthly production capacity had reached 15,000 liters, a capability of which Armour was aware. On January 7,1975, Armour issued a purchase order for calendar year 1975, calling for 3,000 liters per month of “Flash Frozen Plasma” at a price of $42.50 per liter. Because of the dramatic reduction in volume Rothenberg promptly called Eacret and they agreed to meet in Phoenix to resolve their differences. In late January 1975, Rothenberg, Eacret, and another representative of Armour, all met in Phoenix. Eacret succinctly detailed the results of that meeting, testifying:
Well, as I recall, an agreement was reached where Automated Medical Labs would supply additional quantities of plasma on the purchase order [for the January to December 1975 period].
[A]t the meeting, Mr. Rothenberg did mention a quantity of 8000 liters per month [and]
we agreed, verbally to purchase that quantity.
(Emphasis added.)
Between January 7, 1975 and mid-April 1975, Armour accepted delivery of and paid the agreed price for 26,884 liters. Also during this period, Armour informed Auto that it could' no longer use “Flash Frozen Plasma,” but would accept “Normal Fresh Frozen Plasma” at a price of $40.50 per liter. Auto’s agreement to this modification was confirmed in writing.
In late March or early April 1975, Roger Bauer, Eacret’s assistant, called Rothenberg to advise that Armour would no longer accept any shipments, citing an excessive inventory and no market. On April 25, 1975, Armour sent Auto the following telegram:
AS DISCUSSED YOUR LAST PLASMA SHIPMENT TO ARMOUR UNTIL FURTHER NOTICE WILL BE DURING THE WEEK OF 4/21/75.
Armour never resumed purchases from Auto, who remained ready and able to supply 8,000 liters per month. In an effort to mitigate its dilemma, Auto secured a German customer who purchased 2,000 liters per month, commencing June 28, 1975. Auto ceased collecting plasma at three of its centers.
In June 1975, Armour was informed by the Bureau of Biologies, Food and Drug Administration (the Bureau) that five units (approximately 3 liters) of plasma shipped from Auto’s Orlando center in 1974 were possibly contaminated with hepatitis. Armour was also informed that plasma from both the Clearwater and Orlando facilities was under quarantine. Armour promptly notified Auto of this information and asserted' that the questioned plasma did not conform to the warranty specifications of their purchase agreement.
After completing its investigation, the Bureau informed Armour that all plasma from Auto’s Clearwater and Orlando centers which Armour had in process of manufacture as of June 6, 1975 was safe and could be sold. All such plasma “in process” had been shipped prior to January 1, 1975. Any resulting warranty breach, therefore, necessarily arose pursuant" to the terms of the parties’ 1974 contract and not the January 1975 Phoenix agreement.
Upon receiving approval from the Bureau on August 27, 1975, Armour tested over 28,000 units of the suspect plasma. Ninety-nine units of plasma tested “hepatitis positive.” Armour incurred expenses totaling $109,644.51 in its program to sample, test, store, and care for the quarantined plasma.
After weighing the evidence adduced at trial, the district court held: (1) that the January 1975 “Phoenix agreement,” requiring Armour to purchase 8,000 liters of plasma per month at $42.50 per liter, was a binding oral contract for the calendar year 1975; (2) that the contract price was mutually modified in March 1975 to $40.50 per liter; (3) that Armour breached and completely repudiated the contract in April 1975; (4) that Auto was entitled to recover
net damages amounting to $678,027.96, as well as pre-judgment interest on this award; and (5) that due to Auto’s breach of warranty resulting from the hepatitis-contaminated blood, Armour sustained $109,-644.51 in damages, which amount was to be offset against Auto’s damage recovery, resulting in a net award to Auto of $568,-383.45.
On appeal, Armour contends that the Phoenix agreement is not a binding contract because it violates the statute of frauds and that Auto is not entitled to pre-judgment interest because its damages are unliquidated. Auto insists that the contract is binding, that it is entitled to gross damages, rather than net damages, and it challenges the breach of warranty recovery awarded Armour.
The Phoenix Agreement: Bad Contract as Well as Bad Blood?
U.C.C. § 2-201
provides that contracts for the sale of goods valued in excess of $500 are unenforceable unless in writing and signed by or for the respondent party.
Armour claims that the Phoenix agreement, providing for the- purchase/sale of 8,000 liters per month throughout 1975, is unenforceable under § 2-201 because it is not in writing.
Invoking the statute of frauds is an affirmative defense which must be specially pled. Fed.R.Civ.P. 8(c). Although absolute specificity in pleading is not required, fair notice of the affirmative defense is. Fed.R. Civ.P. 8(f). Under the liberalized pleading guidelines codified in the federal rules, ample opportunity to amend pleadings exists with leave to be freely given. Fed.R.Civ.P. 15(a). Thus, while one wishing to assert an affirmative defense has every opportunity to do so, it must be done at a time and in a manner which is consistent with the language and spirit of the federal rules. The court and the opposing party must be timely advised of the intended defense.
In
Funding Systems Leasing Corp. v. Pugh,
530 F.2d 91 (5th Cir. 1976), a virtual “goose case,” we spoke to the time limitations for the assertion of a statute of frauds defense. The defendant in
Pugh
sought to raise this defense in a memorandum supporting his motion for summary judgment filed after entry of the pre-trial order. The pre-trial order, required by Fed.R. Civ.P. 16, listed all defenses, but made no reference to the statute of frauds. In rejecting the defendant's attempt to inject the defense at this stage, we stated:
When the defendant has waived his affirmative defense by failing to allege it in his answer, or have it included in a pretrial order of the district court that supersedes the pleadings,^ he cannot revive the defense in a memorandum in support of a motion for summary judgment. . . . We hold that appellant waived his [statute of frauds] argument by failing to affirmatively set forth this argument in a responsive pleading. Accordingly, the argument cannot be considered on appeal.
530 F.2d at 96.
Application of the
Pugh
rule to the instant case requires an examination of the parties’ Pre-Trial Stipulation which contains the following topics: (1) Pleadings Raising the Issues, (2) Undecided Motions, (3) Stipulated Facts, (4) Facts Not Admitted But Requiring No Proof, and (5) Disputed Matters. There is no mention of a statute of frauds defense in the Stipulation. Under the heading “Pleadings Raising the Issues,” Armour declares that all of its relevant pleadings are contained in a June 2, 1978 “Answer and Counterclaim” and a July 14,1978 “Reply to Affirmative Defenses,” neither of which contains any reference to the statute of frauds.
Armour first mentioned the statute of frauds in a one sentence comment in a Trial Memorandum filed shortly before trial. The reference was repeated in a motion for a directed verdict and in posttrial motions. As did the appellant in
Pugh,
Armour has waived any statute of frauds defense it may have had.
Breach of Contract
Having disposed of the statute of frauds issue, we consider whether the January 1975 meeting in Phoenix produced a binding contract and, if so, whether it was breached. The district court found that an agreement had been reached calling for the purchase/sale of 8,000 liters each month of 1975, for a price of $42.50 per liter, later adjusted to $40.50 per liter. These findings, insofar as they are findings of fact, are not clearly erroneous and are therefore affirmed. Fed.R.Civ.P. 52. The record clearly establishes the agreement; the extract from the testimony of Eacret quoted above reflects the understanding of the parties.
In resolving the breach issue, we note that Bauer’s telephone call, later confirmed by telegram, clearly reflects Armour’s repudiation of the Phoenix accord. U.C.C. § 2-610(c)
directs an aggrieved seller to § 2-704,
which in turn refers the seller to
§ 2-703
and its panoply of available remedies including § 2-706,
(Seller’s Resale Damages), and § 2-708,
(Seller’s Damages for Non-Acceptance or Repudiation), both of which are applicable.
The district court made findings of fact that Auto made repeated but unsuccessful attempts to sell plasma after the breach and ceased collecting plasma at each of its six centers. These findings are clearly erroneous and are rejected. Rothenberg testified that after the Armour breach his company sold 2,000 liters of Flash Frozen Plasma per month to Haemo-Med Company of Frankfurt, Germany. Rothenberg also testified that only the centers in Orlando,
Clearwater and Miami were closed. The other three remained open.
Auto’s “resale”
of 2,000 liters per month to the new customer beginning in June 1975, brings into play the provisions of § 2-706. The district court did not make findings of fact on the resale price or on the incidental expenses associated therewith. We remand in order that the court may make the relevant determinations. In making the calculations mandated by § 2-706, the district court is to use as the contract price the modified per liter price of $40.50.
Computation of Damages
Section 2-708 prescribes the appropriate formula for computing the damages for the unsold plasma.
The district court ruled that Auto was entitled to recover its net profit losses. Net profits are equal to the contract price per liter minus direct costs (payments to donors, costs of blood collection bags, and other costs specifically tied to the
volume
of output under a particular contract) and minus overhead costs (rent, static utility costs at plasma centers, and other costs incurred regardless of the
volume
of output). Auto asserts that it is entitled to recover gross profits. To calculate gross profits, one need only subtract direct costs from the contract price. In that instance, the aggrieved seller would recover overhead costs in addition to net profits.
Florida law governs remedies, accordingly we defer to decisions by the Florida courts for the rules governing seller’s lost profits under § 2-708(2). We find a dispositive decision involving the legal issue now before us,
Tech Corporation v. Permutit Company,
321 So.2d 562, 563 (Fla.App. 1975), in which the court held:
There is no dispute among the parties that if appellee is entitled to recover damages . .., § 672.708(2), F.S.1973, [U.C.C. § 2-708(2)] is applicable and appellee is entitled to recover its lost profit, including reasonable overhead.
The rule enunciated in
Tech
applies to the case at bar
for
as conceded in Armour’s brief, at page 28:
Automated relies on the principle that a seller is entitled to recover lost profits “including reasonable overhead.” U.C.C. § 2-708(2). We do not quarrel with this principle....
Accordingly, we are confronted with the same situation as the Florida court in
Tech.
Because the parties before us are in obvious agreement, we proceed on the basis that § 2-708(2) includes reasonable overhead.
The district court erred in awarding Auto
net profits. In light of the foregoing discussion, and giving substantial weight to the agreement of the parties on this issue, we conclude that Auto is entitled to gross profits, which includes the net profit element and an overhead expense element. In calculating the overhead component, we remind the district court of the teaching of the
Tech
court:
The proof of lost profits and the allocation of overhead to a specific job is at best difficult. The proof concerning the amount of lost profits need only be reasonably certain to permit recovery thereof.
321 So.2d at 563.
The allocation of overhead is particularly problematic because three centers remained open after the breach. The record is unclear as to what extent they remained open to service the Haemo-Med account. Auto’s 1975 overhead costs are not recoverable to the extent they were incurred in servicing a current client. On remand, the court must examine Auto’s 1975 records to determine actual overhead expenses for 1975. Because Auto closed three centers after the Armour breach, its overhead expenses in 1975 may very well have varied considerably from the expenses incurred in previous years. While mathematical certainty in proving damages is not required,
the considerations highlighted above are of major significance, as may be others later found appropriate, and must be evaluated by the district court before determining the damage award due Auto.
Pre-Judgment Interest
The Florida Supreme Court spoke to the question of pre-judgment interest in breach of contract cases in
Parker
v.
Brinson Construction Company,
78 So.2d 873, 874 (Fla. 1955):
This Court has long recognized that in actions ex contractu it is proper to allow interest at the legal rate from the date the debt was due.
Sullivan v. McMillan,
37 Fla. 134, 19 So. 340, 53 Am.St.Rep. 239;
McMillan v. Warren,
59 Fla. 578, 52 So. 825. The fact that there is an honest and bona-fide dispute as to whether the debt is actually due has no bearing on the question. The rule is that if it is finally determined that the debt was due, the person to whom it was due is entitled not only to the payment of the principal of the debt but to interest at the lawful rate from the due date thereof.
Accord, Hatch v. Minot,
369 So.2d 974 (Fla. App.1979);
Peter Marich & Associates, Inc.
v.
Powell,
365 So.2d 754 (Fla.App.1978).
The pivotal question is whether Armour’s debt to Auto was fixed, certain, and therefore liquidated. Answering this question in the affirmative, we hold that Auto is entitled to pre-judgment interest on its final damage award as calculated on remand.
Armour’s contract obligation to Auto was fixed on the date in late January 1975 when the parties met in Phoenix and reached an agreement calling for twelve monthly shipments of 8,000 liters each. Armour’s debt to Auto was certain: originally, the contract price was set at $42.50 per liter, later adjusted by mutual agreement to $40.50 per liter.
Auto’s claim against Armour is liquidated because the dates of contract formation and breach are established, the quantity sold is fixed, as is the contract price. Awarding Auto gross profits, including reasonable overhead costs, does not change our conclusion on this issue.
See Tech,
321 So.2d at 563-64. Contrary to Armour’s contention, we are not faced with a situation where “the amount of the damages cannot be computed except on conflicting evidence, inferences and interpretations.”
Town of Longboat Key
v.
Carl E. Widell & Son,
362 So.2d 719, 723 (Fla.App.1978).
Auto is entitled to recover pre-judgment interest at a rate of six percent'per annum as provided in Fla.Stat. § 687.01.
Armour’s Counterclaim
Damages amounting to $109,644.51 were awarded to Armour as reimbursement for expenses incurred in testing and storing quarantined plasma suspected of being infected with hepatitis. Auto contends that Armour’s counterclaim is barred because it failed to reject or revoke the contract in accordance with U.C.C. §§ 2-606 and 2-608. Auto’s reliance on these provisions is misplaced because it is beyond dispute that Armour accepted the questioned plasma and did not attempt to revoke the 1974 contract. As an aggrieved buyer, Armour is protected both by § 2-314
(Implied Warranty of Merchantability) and § 2-315
(Implied Warranty of Fitness for a Particular Purpose). The implied warranty of merchantability was breached when Auto failed to suitably screen the plasma for hepatitis. The plasma was not “fit for the ordinary purposes for which such goods are used.” § 2-314(2)(c). Further, Armour gave Auto an implied warranty of fitness for a particular purpose. All purchase orders sent to Auto by Armour stated that Auto had agreed to screen for hepatitis. Quite obviously, Armour knew that the plasma would be used on human patients and, therefore, had to be “hepatitis negative.” Armour was relying on Auto, with its fully equipped collection centers and labs, to check all plasma for any trace of hepatitis. The particular purpose fitness warranty was also breached.
Auto attacked the award of counterclaim damages on several other grounds. Our examination of the record discloses no merit in any of these and, accordingly, all are rejected.
The judgment of the district court is AFFIRMED in part, REVERSED in part, and REMANDED for such further proceedings as the district court may deem appropriate and, thereafter, entry of judgment not inconsistent herewith.